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ABSTRACT
Background. Platelet volume indices (PVI) such as 
mean platelet volume (MPV), platelet distribution 
width (PDW), and platelet large cell ratio (P‑LCR) 
are the indicators of platelet activity and may have 
a role in subclinical atherosclerosis and microvascular 
complications in type 2 diabetes mellitus (T2DM). We 
evaluated PVI in diabetics for their association with 
carotid intima media thickness (CIMT) and micro‑
vascular complications.
Methods. Participants — 105 T2DM patients and age, 
gender matched 105 controls were evaluated by his‑
tory and complete blood counts (CBC) including PVI, 
blood sugars, HbA1c, lipid profile and microvascular 
complications. PVI were compared between cases and 
controls. Carotid Doppler was done and CIMT was cor‑
related with PVI. 
Results. PVI were found significantly higher in diabetic 
patients compared to controls. Mean MPV in cases vs. 
controls was (11.09 ± 1.02 fL vs. 10.28 ± 0.96 fL, p £ 
0.001), mean PDW (13.46 ± 1.96 fL vs. 12.85 ± 3.54 
fL, p = 0.12), mean P‑LCR (31.92 ± 6.23% vs. 27.94 ± 
5.94%, p £ 0.001). CIMT showed a positive significant 
association with MPV, PDW and PLCR, dyslipidemia and 
negative with glycemic control. PVI, especially MPV 
was significantly elevated in those with neuropathy, 
nephropathy and retinopathy.
Conclusion. PVI i.e. MPV, PDW, P‑LCR are increased in 
diabetic patients. They correlate positively with CIMT, 
implying cardiovascular risk. PVI have a positive asso‑
ciation with microvascular complications also. PVI as 
determined by simple automated CBC can be used as 
markers of subclinical atherosclerosis and predictor of 
future cardiovascular events in T2DM. (Clin Diabetol 
2020; 9)
Key words: T2DM, PVI, increased CIMT, microvascular 
complications
Introduction
In T2DM, platelets and their interaction with the 
vessel wall play a role in atherogenesis and in the forma-
tion of the coronary thrombus. Several haemorrheologi-
cal alterations take place in both T1DM and T2DM. The 
erythrocytes are altered and become less deformable, 
contributing to increased whole blood viscosity. The 
platelet function is also altered in diabetes. Diabetic 
thrombocytopathy refers to differences in platelet 
function between diabetic and nondiabetic individu-
als. Among diabetic individuals, differences are due to 
the following: reduced membrane hydration, altered 
Ca2+ and Mg2+ homeostasis (increased intracellular 
Ca2+ mobilization and decreased intracellular Mg2+), 
increased arachidonic acid metabolism, increased TXA2 
synthesis, decreased prostacyclin production, decreased 
NO production, decreased antioxidant levels, increased 
expression of activation-dependent adhesion molecules 
(e.g., GpIIb–IIIa, P-selectin) [1].
Platelets from patients with type 1 and type 2 
diabetes exhibit enhanced platelet aggregation acti-
vity early in the disease course that may precede the 
development of cardiovascular disease (CVD). Numer-
ous biochemical abnormalities have been found that 
correlate with platelet hyperreactivity. Platelets from 
diabetic patients exhibit reduced membrane hydration 
as described above, which may reflect changes in the 
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lipid composition of the membrane or glycation of 
membrane proteins. Arachidonic acid metabolism is 
increased in platelets from diabetic patients; this leads 
to enhanced TXA2 production and may contribute to 
increased platelet sensitivity. Platelets in type 2 dia-
betic individuals adhere to vascular endothelium and 
aggregate more readily than those in healthy people. 
Loss of sensitivity to the normal restraints exercised by 
prostacyclin [PGI (2)] and nitric oxide (NO) generated by 
the vascular endothelium presents as the major defect 
in platelet function. Insulin is a natural antagonist of 
platelet hyperactivity. It sensitizes the platelet to PGI (2) 
and enhances endothelial generation of PGI (2) and NO. 
Thus, the defects in insulin action in diabetes create a 
milieu of disordered platelet activity conducive to mac-
rovascular and microvascular events [2]. Platelet size is 
also increased in diabetes. The large platelets having 
dense granules are more active biochemically, function-
ally, and metabolically, have higher thromboxane A2 
levels, express more glycoprotein Ib and IIb/IIIa recep-
tors, and could be a risk factor for developing coronary 
thrombosis [3]. Patients with type 2 diabetes mellitus, 
without proven vascular disease, exhibit platelet dys-
function and have increased platelet aggregation and 
aspirin insensitivity compared to non-diabetic patients 
with previous MI [4]. 
Many researchers have found an association be-
tween mean platelet volume, cardiovascular events 
like acute MI and glycemic status. There are reports of 
negative association also. Hence, we wanted to explore 
the relation between T2DM and all platelet volume 
indices and whether these indices which are available 
as a part of complete blood counts as determined by 
automated counters, can be used as markers of future 
cardiovascular events. 
The first structural change that can be detected in 
atherosclerosis is an increase in intima-media thickness 
(IMT). The value of CIMT as a surrogate endpoint in 
interventional or observational studies as an alterna-
tive to cardiovascular disease (CVD) is strengthened 
by its associations with risk factors and coronary or 
cerebrovascular events.      
In this study, all components of platelet volume 
indices were compared with controls to see if they 
are altered in T2DM and if they are associated with 
increased CIMT and can be used as marker of subclini-
cal atherosclerosis.
Methods 
This hospital-based case control study was carried 
out in our tertiary care Centre from Januar 2016 to 
August 2017 after approval from institutional ethical 
committee. 
Study population
105 consecutive patients of T2DM were selected 
from Diabetes Clinic and Medicine outpatient depart-
ment. 105 healthy age and gender matched non-
diabetic visitors or relatives, or unrelated attendants 
of hospitalized patients were selected as controls after 
written informed consent.
Eligibility criteria
Cases: T2DM in age ≥ 30 years diagnosed by ADA 
criteria.
Patients were excluded if they had diabetes other 
than T2DM, any acute complications of diabetes, acute 
infections, critical illness, myeloproliferative disorders, 
thrombocytopenia due to any other cause e.g. immune 
thrombocytopenia, hemoglobin < 10 g/dL in females 
and < 11 g/dL in males, pre-existing peripheral vascular 
disease, stroke and/or angiographically proven coronary 
artery disease (CAD) with or without revascularization, 
or on antiplatelet drugs the controls were age and sex 
matched healthy subjects. Exclusion criteria for controls 
were same as those for cases.
Detailed diabetic history with respect to onset, 
duration, treatment and hypoglycaemic episodes was 
obtained. Relevant history, personal history, any ad-
dictions or drug abuse and socioeconomic data was 
recorded. Cardiovascular risk factors were evaluated in 
all patients according to standard definitions. *Smok-
ers included current smokers and ex-smokers of < 12 
months, whereas non-smokers included ex-smokers of 
more than 12 months and never smokers. **Alcoholism 
was defined as more than 14 drinks per week in men 
and more than 7 drinks in women. ***Hypertensives 
included patients on antihypertensive medications or 
newly detected hypertension as per JNC VIII criteria. 
#Positive family history was defined as occurrence of 
CAD or sudden cardiac death in first degree relatives 
before 40 years of age. ##Dyslipidemia was defined as 
serum (Sr) cholesterol > 200 mg/dL and/or serum tri-
glycerides > 150 mg/dL and/or serum HDL < 40 mg/dL 
in males and < 50 mg/dL in females (Table 1). 
Physical measurements specifically height, weight, 
BMI, were recorded and blood pressure measurements, 
electrocardiogram were done in each patient.
All patients were evaluated for macro and micro-
vascular complications of diabetes. Those with mac-
rovascular complications were excluded. Evaluation 
for microvascular complications was done as follows 
— peripheral neuropathy: assessed by Toronto Clinical 
neuropathy score and SW monofilament test. Diabetic 
retinopathy was assessed by fundus examination through 
dilated pupil by ophthalmologist and diabetic nephropa-
thy was assessed by microalbuminuria and eGFR.
Riya M Waghale et al., T2DM, platelet volume indices, increased CIMT
3
CBC, fasting and post-meal blood sugar, lipid profile, 
microalbuminuria, Sr creatinine, eGFR by Cockcroft Gault 
formula and glycosylated haemoglobin (HbA1c) by stand-
ardized HPLC method were performed in all cases. In 
controls CBC for PVI and fasting, post meal blood sugar 
and HbA1c and other relevant investigations were done.
Platelet volume indices [5] — the PVI are univer-
sally available with routine blood counts by automated 
Table 1. Baseline characteristics, cardiovascular risk factors and PVI in cases and controls





1. Age in years
Mean ± SD (range) 55.5 ± 10.3  
(31–80)




Males 48 (46%) 48 (46%)  1.00
Females 57 (54%) 57 (54%)
3. Hemoglobin [g/dL] 12.7 ± 1.34 12.31 ± 0.23 0.73
Mean ± SD
4. Total leucocyte 8.32 ± 2.66 7.8 ± 3.49 0.815
Count [103/cu mm]
Mean ± SD
MPV (fL) p‑value PDW (fL) p‑value P‑LCR (%) p‑value
5. Duration of DM 
< 5 yrs (n = 66) 10.73 ± 0.81 < 0.05 12.82 ± 1.41 < 0.05 29.51 ± 4.83  < 0.05
≥ 5 yrs (n = 39) 11.73 ± 0.73 14.54 ± 1.41 36.72 ± 3.74
6. Glycemic status
HbA1c < 7% (n = 22) 10.95 ± 0.69 0.48 12.98 ± 1.37 0.19 30.81 ± 4.54 0.35
HbA1c ≥ 7% (n = 83) 11.12 ± 1.1 13.59 ± 2.08 32.22 ± 6.64
7. Cardiovascular risk factors
a Smokers* (n = 24) 11.23 ± 0.99  
(9.1–13.6)
0.45 13.54 ± 1.75 
(9.6–17.1)
0.82 32.74 ± 6.19 
(17.6–43.5)
0.47
Non smokers (n = 81) 11.05 ± 1.04 13.44 ± 2.03 31.68 ± 6.31
b Alcoholics** (n = 18) 11.16 ± 1.2 
(9.1–13.6)
0.75 13.26 ± 1.95 
(9.6–17.1)
0.63 31.69 ± 6.97 
(17.6–43)
0.86
Non alcoholics (n = 87) 11.07 ± 0.99 13.51 ± 1.97 31.97 ± 6.16
c Hypertensives*** (n = 41) 11.31 ± 1.11 
(9.1–14)
0.06 13.85 ± 2.23 
(9.6–20.2)
0.11 33.35 ± 6.8 
(17.6–46.7)
0.06
Non hypertensives (n = 64) 10.94 ± 0.94 13.22 ± 1.74 31.01 ± 5.76
d Family history of CAD present# 
(n = 30)
11.74 ± 0.94 
(9.9–13.6)
< 0.001 14.78 ± 2.19 
(11.1–20.2)
< 0.001 35.8 ± 6.21 
(19.5–46.7)
< 0.001
No family history of CAD  
(n = 75)
10.83 ± 0.94 12.94 ± 1.59 30.37 ± 5.62
e BMI [kg/m2] 
18–24.9 (n = 70)
10.58 ± 0.96 p < 0.001 
(for trend)
12.69 ± 1.75 p < 0.001 
(for trend)
28.8 ± 5.68 p < 0.001 
(for trend)
25–29.9 (n = 21) 10. 86 ± 0.57 14.01 ± 1.48 34.74 ± 4.38
30–34.9 (n = 10) 12.43 ± 0.33 14.27 ± 2.45 33.85 ± 5.93
≥ 35 (n = 4) 11.33 ± 1.21 14.83 ± 2.89 35.45 ± 7.01
f Dyslipidemia## 
Present (n = 64)
11.28 ± 1.15 
(9.1–14)
0.01 13.8 ± 2.21 
(9.6–20.2)
0.02 32.8 ± 7.08 
(17.6–47.5)
0.07
Absent (n = 41) 10.79 ± 0.72 12.93 ± 1.35 30.55 ± 4.49
MPV — mean platelet volume; PDW — platelet distribution width; P-LCR — platelet large cell ratio; DM — diabetes mellitus; BMI — body mass index
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hemograms. Following PVI were studied in cases and 
controls.
Platelet count: Platelet counts are laboratory 
measure of concentration of platelets in blood. The 
standard ranges from 1.5 to 4.5 × 106/cu mm.
Mean platelet volume (MPV): This parameter 
provides a statement on the MPV between the lower 
discriminator and the upper discriminator. The standard 
ranges from 8 to 12 fL.
Platelet distribution width (PDW): PDW indicates 
the platelet distribution width measured at 20% relative 
height of the total height of the curve. An increased 
PDW is an indicator for the anisocytosis of platelets. 
Standard PDW ranges from 9 to 14 fL.
Platelet large cell ratio (P‑LCR): P-LCR indicates 
the percentage of large platelets with a volume > 
12 fL and is presented in %. The standard range is 
15–35%. An increase may be an indication for platelet 
aggregates, micro erythrocytes and giant platelets also 
regenerating large platelets.
Plateletcrit (Pct): Plateletcrit is equivalent to 
the sum of platelet impulses which are individually 
detected by means of the impedance measurement 
principle and thus it is the platelet equivalent to the 
hematocrit of the RBCs. The standard ranges from 
0.22 to 0.24%.
Carotid intima medial thickness: Carotid Dop-
pler was done by single expert sonologist in all cases 
evaluating both the carotid arteries. Thickening of the 
intima-media greater than 0.8 mm was considered as 
abnormal and represented the earliest change of ath-
erosclerosis. Cut-off was based on findings of screen-
ing of normal persons and patients with subclinical 
atherosclerosis prior to this study at our institute by 
qualified sonologist. Carotid plaques and percentage 
carotid stenosis were also determined. The far wall of 
the common carotid artery 1–2 cm proximal of carotid 
bulb was used for measurement. The leading edge 
of vascular lumen-intima was selected as the internal 
measurement site and the leading edge of the media-
adventitia as the external limit. The measurement was 
repeated twice at the same site and then performed 
in the same way three times at the corresponding op-
posite site. Mean of CIMT of three sites of a side was 
taken for calculation of CIMT of that side. 
Statistical analysis
Collected data was entered in MS-Excel 2010 and 
corrected for typographic errors and analyzed using 
SPSS 16.0 version. Descriptive statistics like proportions, 
mean and standard deviation was used for continu-
ous variables. For categorical variables, chi-square test 
was used. To decipher independent association of PVI 
with CIMT, multiple logistic regression analysis was 
done with CIMT as the dichotomous outcome variable 
(dependent variable). Independent T test (unpaired t 
test) was used to compare between two groups and 
ANOVA was used to compare the continuous variables 
among more than two groups. The confidence limit for 
significance was fixed at 95% level with p-value < 0.05.
Results
It was observed that out of 105 cases and controls, 
48 (46%) were males and 57 (54%) were females with 
a M:F ratio 1:1.2. Most cases (34%) and controls (32%) 
were in the age group of 51–60 years. In controls, as 
the age advanced, mean of all platelet indices increased 
and the difference was statistically significant. The MPV 
increased from 10.8 ± 0.91 in 32–40 years age group 
to 11.7 ± 0.82 in 71–80 years age group (p = 0.01). 
This was not observed in diabetics. This could be due to 
baseline increase in MPV, PDW, P-LCR in diabetics due 
to disease itself. Hence the age-related increment did 
not occur. There was no significant difference in mean 
MPV, PDW and P-LCR based on gender. 
Most patients (59%) had duration of diabetes of 
more than 5 years, 11.4% cases were newly diagnosed 
and 11.4% had diabetes of more than 10 years. The 
mean PVI gradually increased with duration of diabetes 
up to10 years and were significant for MPV, PDW and 
P-LCR. Beyond 10 years, PVI were not much altered. This 
could be explained as number of patients with duration 
greater than 10 years were much less (11%) and the 
disease related changes in these platelet indices had al-
ready occurred and may have reached a plateau (Table 1).
PVI in T2DM as compared to healthy controls
It was observed that all the platelet indices except 
platelet count were increased in diabetics as compared 
to healthy controls. 16% of diabetics had increased 
MPV, 34% had increased PDW, 26% had increased 
P-LCR and 76% had increased plateletcrit as compared 
to 1%, 15%, 23%, 63% controls respectively. Platelet 
count was within normal range. Mean of MPV, PDW, 
P-LCR and plateletcrit were also increased in cases as 
compared to controls, however statistically significant 
increase was observed only in MPV and P-LCR (Table 2).
Cardiovascular risk factors and PVI
Dyslipidemia (61%) (increased cholesterol and 
triglycerides and decreased HDL) was the most com-
mon cardiovascular risk factor in diabetics followed by 
hypertension (40%), BMI ≥ 25 kg/m2 (34%) and family 
history of IHD (28.6%).
Mean MPV, PDW were significantly increased in pa-
tients with hypercholesterolemia, and mean MPV, PDW 
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and P-LCR were significantly increased in patients with 
hypertriglyceridemia. Mean MPV, PDW and P-LCR were 
significantly increased in female patients with HDL less 
than 50 mg/dl as compared to those with normal levels. 
PVI like MPV, PDW and P-LCR were significantly 
increased in cases with BMI ≥ 25 and family history 
of IHD. There was no significant association of PVI 
with CV risk factors like hypertension, alcoholism and 
smoking (Table 1).
Carotid atherosclerosis and platelet  
volume indices
All diabetics underwent carotid doppler and it was 
observed that on right side, 44% patients had CIMT < 
0.8 mm, 55% had CIMT ≥ 0.8 mm. On left side, 46% 
had CIMT < 0.8 mm, 53% had CIMT ≥ 0.8 mm. The 
mean CIMT of both sides were comparable (0.78 ± 
0.22 mm on right and 0.79 ± 0.23 mm on left). On 
right side, 4.7% cases had < 50% stenosis and exactly 
equal cases had ≥ 50% stenosis, whereas on left, 7.6% 
cases had < 50% stenosis and no patient had ≥ 50% 
stenosis. Plaques without significant occlusion were 
detected on right side in 20.9% and on left side in 
8.5% cases. When PVI were correlated with CIMT it was 
observed that mean MPV, PDW, P-LCR were significantly 
increased, plateletcrit was marginally increased and 
mean platelet count was decreased in patients with 
CIMT ≥ 0.8 (Table 3).
When mean CIMT was plotted against these PVI, 
it was observed that MPV, PDW and P-LCR had moder-
ate positive linear relationship which was statistically 
significant. Platelet count had weak negative linear re-
lationship (r = –0.231) and was statistically significant. 
However, plateletcrit had no relationship with CIMT.
Multiple logistic regression analysis with CIMT 
as dichotomous dependent outcome variable 
and significant cardiovascular risk factors as 
independent predictor variable
MPV was significantly associated and had positive 
co-relation with age (r = 0.335, p < 0.001), duration 
of DM (r = 0.437, p < 0.001), BMI (r = 0.268, p = 
0.006), cholesterol (r = 0.297, p = 0.002), triglyceride 
(r = 0.204, p = 0.03), LDL-C (r = 0.222, p = 0.02) and 
CIMT (r = 0.638, p < 0.001). MPV was significantly but 
negatively co-related to HDL-C (r = –0.307, p < 0.001). 
No association existed between MPV and HbA1c.
On MLR analysis, when platelet indices were as-
sessed as independent risk factors after controlling 
for BMI, dyslipidemia and positive family history of 
IHD, they were not significant. On univariate analysis, 
MPV, PDW and P-LCR were significantly associated with 
increased CIMT. Hence it can be concluded that MPV, 
PDW and P-LCR are not independent cardiovascular 
risk factors but may have an effect in association with 
conventional risk factors, leading to subclinical athero-
sclerosis as determined by increased CIMT (Figure 1).
Association of PVI with microvascular  
complications of T2DM
Mean MPV, PDW and P-LCR were significantly higher, 
and mean platelet count was significantly lower in pa-
tients with retinopathy as compared to those without 
retinopathy. Mean MPV, PDW and P-LCR were signifi-
Table 2. Platelet volume indices (PVI) in T2DM and non‑
diabetics
PVI Cases (T2DM) 
(n = 105) 
Controls  
(nondiabetics) 
(n = 105) 
p‑value
MPV (fL) 11.09 ± 1.02 
(8.2–14)
10.28 ± 0.96 
(6–12.1)
< 0.001
PDW (fL) 13.46 ± 1.96 
(9.4–20.2)
12.85 ± 3.54 
(4.2–38.6)
0.12
P-LCR (%) 31.92 ± 6.23 
(17.6–47.5)
27.94 ± 5.94 
(14.5–39.5)
< 0.001
Platelet count  
(106/cu mm)
2.69 ± 0.55 
(1.63–4.26)
2.82 ± 0.69 
(1.5–4.57)
0.14
Plateletcrit (%) 0.29 ± 0.05 
(0.18–0.47)
0.28 ± 0.07 
(0.13–0.5)
0.18
MPV — mean platelet volume; T2DM — type 2 diabetes mellitus;  
PDW — platelet distribution width; P-LCR — platelet large cell ratio
Table 3. Association of platelet volume indices (PVI) with 
carotid intima media thickness (CIMT)
PVI 
Mean + SD 
(range)
CIMT < 0.8 
(n = 49)
CIMT ≥ 0.8 
(n = 56)
p‑value
MPV (fL) 10.57 ± 0.83 
(8.2–12.8)
11.53 ± 0.97 
(9.1–14)
< 0.001 
PDW (fL) 12.53 ± 1.39 
(9.4–16.1)
14.28 ± 2.03  
(9.6–20.2)
< 0.001 
P-LCR (%) 28.66 ± 4.78 
(19.3–42.5)
34.76 ± 6.06 
(17.6–47.5)
< 0.001
Platelet count  
(106/cu mm)
2.75 ± 0.60 
(1.75–4.26)
2.65 ± 0.51 
(1.63–3.52)
0.37
Plateletcrit (%) 0.27 ± 0.06 
(0.18–0.47)
0.29 ± 0.054 
(0.19–0.4)
0.14
MPV — mean platelet volume; PDW — platelet distribution width; P-LCR 
— platelet large cell ratio
Clinical Diabetology 2020, Vol. 9
6
cantly higher, and mean platelet count was lower but 
non-significantly in patients with neuropathy as com-
pared to those without neuropathy. Mean MPV, PDW 
and P-LCR were significantly higher, and mean platelet 
count was significantly lower in patients with nephropa-
thy as compared to those without nephropathy (Table 4).
Discussion
Diabetes is considered as a ‘prothrombotic’ state. 
Platelet activation is an important factor, the determi-
nants of which are platelet volume indices i.e. mean 
plate volume (MPV), platelet distribution width (PDW) 
and platelet large cell ratio (P-LCR). When we compared 
the PVI in T2DM with healthy controls we observed that 
MPV, P-LCR were significantly increased in diabetics. 
PDW and plateletcrit were increased but statistically 
insignificant and platelet counts were unaltered. In 
diabetes, there is increased thrombopoiesis and cir-
culation of large, young and activated platelets which 
undergo more frequent episodes of release of granules, 
accelerated sequestration in the circulation and have 
reduced survival, thus platelet count is decreased. As 
plateletcrit is the volume occupied by platelets in the 
blood as a percentage, and directly related to platelet 
count, both the indices decrease in diabetics. However, 
no such decrease in plateletcrit was seen in our study. 
Factors that contribute directly to greater platelet 
reactivity in diabetics include metabolic abnormalities 
such as hyperglycemia and hyperlipidemia, both insu-
lin resistance (relative insulin deficiency) and absolute 
insulin deficiency, as well as associated conditions 
such as oxidative stress, inflammation, and endothelial 
dysfunction [6].
Many studies have reported increase in MPV in 
diabetics as compared to non-diabetics. Our results 
were in accordance to studies done by Kodiatte et al. 
[7], Papanas et al. [8], and Alhadas et al. [9]. Hekimsoy 
et al. [10] also reported increased MPV in diabetics but 
Figure 1. Multiple logistic regressions with CIMT as dichotomous dependent outcome variable. MPV — mean platelet volume; 
PDW — platelet distribution width; P-LCR — platelet large cell ratio
Table 4. Association of platelet volume indices (PVI) with microvascular complications
Complication MPV (fL) p‑value PDW (fL) p‑value P‑LCR (%) p‑value
Retinopathy present (n = 29) 12.09 ± 0.88  
(10.3–14)
< 0.001 15.33 ± 1.94 
(12–20.2)
< 0.001 37.83 ± 5.09 
(25.1–47.5)
< 0.001 
Retinopathy absent (n = 76) 10.7 ± 0.79  
(8.2–12.5)
12.75 ± 1.44 
(9.4–16.1)
29.67 ± 5.12  
(17.6–42.5)
Neuropathy present (n = 27) 11.86 ± 0.88  
(9.7–13.6)
< 0.001 14.72 ± 1.74 
(11–19.9)
< 0.001 36.26 ± 5.44 
(22.8–47.5)
< 0.001
Neuropathy absent (n = 78) 10.82 ± 0.93  
(8.2–14)
13.03 ± 1.85 
(9.4–20.2)
30.42 ± 5.85 
(17.6–46.7)
Nephropathy present (n = 55) 11.54 ± 1.03  
(9.2–14)
< 0.001 14.33 ± 2.03  
(11–20.2)
< 0.001 34.7 ± 6.27 
(22.8–47.5)
< 0.001
Nephropathy absent (n = 50) 10.58 ± 0.75  
(8.2–12.4)
12.51 ± 1.36  
(9.4–14.8)
28.8 ± 4.67 
(17.6–38.2)
MPV — mean platelet volume; PDW — platelet distribution width; P-LCR — platelet large cell ratio
1.04 (0.62–1.74)
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reported low platelet counts in diabetics. We did not 
observe any alteration in platelet counts in diabetics. 
MPV is an indicator of the average size and activity of 
platelets. Larger platelets are younger, more reactive 
and aggregable. Hence, they contain denser granules, 
secrete more serotonin and b-thromboglobulin, and 
produce more thromboxane A2 than smaller platelets. 
MPV reflects the state of thrombogenesis. There might 
be small bleeds due to the rupture of atherothrombotic 
plaques leading to increased platelet recruitment, hyper 
reactivity, and bone marrow stimulation. Thus, high 
MPV is emerging as a new risk factor for the vascular 
complications of DM of which atherothrombosis plays 
a major role [7]. Many researchers have observed an 
association of increased MPV with cardiovascular 
events like myocardial infarction and acute coronary 
syndrome. We did find an increased PDW in diabet-
ics, but the difference was statistically insignificant. 
Contrary to this Jindal et al. [11] observed that PDW 
was significantly higher in diabetics. It could be due to 
larger platelets being hyper-reactive produce more pro-
thrombotic factors. Platelet activation causes changes 
in platelet morphology and formation of pseudopodia. 
The enlarged platelets with lots of pseudopodia differ 
in the size, possibly affecting the platelet distribution. 
Our study also observed statistically significant increase 
in P-LCR which implied that platelet size was larger in 
diabetics. This finding has been corroborated by many 
studies.
Studies have shown that platelet count and size 
might be gender and age dependent. Advanced age 
was directly associated with increased MPV as conclud-
ed in a study by Lippie et al. [12], where they attributed 
this increase in platelet volume to other cardiovascular 
risk factors like hypertension, dyslipidemia etc. that 
occur with advancing age. We observed that MPV, 
PDW and P-LCR also increased significantly with age in 
controls, but not in diabetics. There was no significant 
association of platelet count and plateletcrit with age. 
It was observed that platelet count and plateletcrit 
was increased significantly in females as compared to 
males. It was in accordance with a study by Bain et al. 
[13]. The difference can possibly be ascribed to the dif-
ferent hormonal profiles amongst the gender or the ef-
fect of menstrual cycle on the haemostatic mechanism 
as thrombocytosis is associated with bleeding. There 
were no significant differences among the genders with 
respect to MPV, PDW or P-LCR.
When conventional cardiovascular risk factors were 
studied, it was observed that, dyslipidemia (61%) was 
the most common risk factor in diabetics followed by 
hypertension (40%), BMI ≥ 25 kg/m2 (34%) and family 
history of CAD (28.6%). In controls, dyslipidemia (28%) 
was the most common risk factor followed by hyper-
tension (27%), smoking (19%), and family history of 
CAD (17%). PVI were significantly higher in diabetics 
with dyslipidemia (MPV and PDW), family history of 
CAD (MPV, PDW and P-LCR) and BMI ≥ 25 kg/m2 (MPV, 
PDW and P-LCR). PVI were high in patients with hyper-
tension and smoking but statistically not significant. 
Nechita et al. [14] also observed that patients with 
cardiovascular risk factors, especially complex ones 
like the metabolic syndrome had an increased MPV, 
as did the patients with unstable angina whether as-
sociated with the risk factors. They implied that MPV 
could be used to differentiate unstable angina from 
non-cardiac chest pain. In a study by Swaminathan et 
al. [15] MPV was found to be higher in subjects with 
type 2 diabetes and significantly increased in diabet-
ics with poor glycemic control and having a longer 
duration of diabetes. In contrast to most studies we 
did not find a significant association between PVI and 
glycemic control [16].
PVI and carotid intima media thickness
Carotid doppler was performed in all diabetics and 
patients were divided in 2 groups based on CIMT; CIMT 
< 0.8 and CIMT ≥ 0.8 mm. PVI were compared between 
2 groups. It was observed that mean MPV, PDW, P-LCR 
were increased significantly in patients with CIMT ≥ 0.8. 
Mean platelet count was decreased and plateletcrit was 
increased but statistically insignificant.
In diabetic patients, hyperglycemia impairs vascular 
endothelial cells and NO production which contributes 
to the formation of atherosclerosis by mediating leu-
kocyte activation and adhesion to the endothelium via 
platelet P-selection [17]. As the platelets participate in 
the formation of atherosclerotic plaque, they are con-
sumed and platelet count may decrease with or after 
the development of atherosclerosis. Our study revealed 
that platelet count has weak negative linear relationship 
with CIMT (r = –0.231) which was statistically signifi-
cant. Also, other indices like MPV, PDW and P-LCR had 
moderate positive linear relationship with CIMT which 
was statistically significant. However, plateletcrit had 
no relationship with CIMT.
Many efforts have focused on the elucidation of 
common pathophysiological mechanisms in obesity, 
type 2 diabetes and atherosclerosis, supporting the 
role played by inflammation. A feature of inflammatory 
activity is the increase in circulating plasma of acute-
phase proteins produced by the liver such as C-reactive 
protein (CRP) and fibrinogen. Fibrinogen levels have 
been shown to be associated with enhanced platelet 
aggregation and smooth muscle cell proliferation. 
Furthermore, there is a strong association of fibrino-
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gen with blood viscosity and thrombus formation and 
circulating levels of fibrinogen have been known to 
have a strong and consistent relationship with CAD 
[18]. However, in our study we did not estimate the 
hsC-reactive protein or fibrinogen levels, and this is a 
limitation of this study which may have overemphasized 
the role of platelet indices.
According to Wan et al. [19] MPV had a high posi-
tive correlation with IMT (p < 0.001). Adam et al. [20] 
in their correlation analysis showed a positive associa-
tion between PDW and the degree of carotid stenosis. 
However, they did not find a significant correlation 
between carotid stenosis and MPV. According to study 
by Yilmaz et al. [21] the calcified plaque group was 
compared with the non-calcified plaque group in terms 
of MPV and PDW. The findings of their study indicated 
that the non-calcified plaques that cause intermediate 
carotid artery stenosis are associated with a significantly 
higher MPV value compared to the calcified plaques. 
There was no difference between the two groups with 
respect to PDW values. However, study by Kim et al. 
[22] found that MPV was strongly associated with the 
severity of glycemic control but not significantly associ-
ated with the early and late stages of atherosclerotic 
vascular changes in type 2 diabetes mellitus patients. 
They concluded that MPV is not a reliable marker for 
subclinical atherosclerosis in a diabetic population. This 
was possibly confounded by the close association of 
MPV with poor glycemic control.
Thoracic aortic intima-media thickness (IMT) was 
reported as an earlier marker of preclinical atheroscle-
rosis than carotid IMT. Yüksel Kalkan et al. [23] reported 
that MPV is independently related to the extent of sub-
clinical thoracic aortic atherosclerosis .Thus increases 
in MPV may be a crucial biochemical marker for initial 
atherosclerosis.
On multiple logistic regression analysis with CIMT 
as dichotomous dependent outcome variable and 
significant cardiovascular risk factors as independent 
variables, it was observed that MPV, PDW and P-LCR 
were not independent risk factors for cardiovascular 
disease, but had an effect in association with conven-
tional risk factors, leading to subclinical atherosclerosis 
as determined by increased CIMT, although on univaria-
te analysis, these PVI were significantly associated with 
increased CIMT. 
If vascular damage was only due to increased 
number of large and reactive platelets, then the rate of 
damage would have been constant for the duration of 
disease and independent of diabetic control. This clearly 
shows that platelet reactivity alone cannot explain the 
progression of vascular complications in DM since there 
are other vascular risk factors that may be influenced 
by degree of control of diabetes. Platelet number and 
reactivity along with cardiovascular co-morbidities such 
as hypertension, albuminuria, obesity, cigarette smok-
ing, and dyslipidemia also contribute to progression of 
diabetes and its effect on PVI. Thus, it shows that there 
are other factors which may account for the thrombotic 
potential of diabetics.
According to Alvitigala et al. [24] and Majumdar 
et al. [25] PVI have the potential to be used as a pre-
liminary test to identify high-risk patients for myo-
cardial infarction along with other supportive clinical 
investigations.
PVI and microvascular complications 
Studies have found an association between 
increased MPV and CAD but very few studies have 
explored the relation between PVI and all the microvas-
cular complications. In our study, diabetic nephropathy 
(82%) was the most common microvascular complica-
tion, followed by retinopathy (46%), and neuropathy 
(46%). MPV, PDW and P-LCR were significantly higher 
in diabetics with microvascular complications. Platelet 
count was significantly increased in retinopathy and 
nephropathy but insignificantly in neuropathy. Papanas 
et al. [8] found that MPV was higher in patients with 
microvascular complications. Ates et al. [26] proved an 
association between degree of retinopathy and mean 
MPV. Buch et al. [27] and Alhadas et al. [9] concluded 
that MPV and PDW were significantly associated with 
microvascular complications. Jindal et al. [11], found 
that only PDW was significantly higher in diabetics with 
complications. This suggests a role of the enhanced 
platelet activity in the pathogenesis of microvascular 
complications.
Thus, PVI namely MPV, PDW, P-LCR are increased 
in diabetics and have a positive association with 
increased CIMT. They also correlate with all 3 mi-
crovascular complications of diabetes. They are not 
independent predictors but may be useful marker 
of carotid atherosclerosis in association with other 
cardiovascular risk factors.
Limitations of the study
Time bound study with relatively small sample size. 
Many confounding factors for poor glycemic control 
and increased complications in our subset of patients 
may have overestimated the association of platelet vol-
ume indices with microvascular complications. Also, we 
could not estimate hs CRP and fibrinogen levels which 
are also surrogate markers of inflammation associated 
with atherosclerosis.
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